This is a preview of subscription content, log in via an institution to check access.
Notes
$US270 000 for treatment of a typical TTP episode
Reference
Goshua G, et al. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood : 6 Dec 2020. Available from: URL: http://doi.org/10.1182/blood.2020006052
Rights and permissions
About this article
Cite this article
Caplacizumab not cost effective for treating acquired thrombotic thrombocytopenic pupura. PharmacoEcon Outcomes News 869, 4 (2021). https://doi.org/10.1007/s40274-021-7371-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7371-2